The Full Wiki

More info on LY-404,187

LY-404,187: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

LY-404,187
Systematic (IUPAC) name
N-[2-(4'-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
Identifiers
CAS number 211311-95-4
ATC code  ?
Chemical data
Formula C19H22N2O2S 
Mol. mass 342.45 g/mol
SMILES eMolecules & PubChem
Synonyms LY-404,187; N-2-[4-(4-cyanophenyl)phenyl]propyl-2-propanesulfonamide
Therapeutic considerations
Pregnancy cat.  ?
Legal status Investigational New Medicine

LY-404,187 (or LY404187) is an ampakine (or "AMPA receptor potentiator") developed by Eli Lilly and Company.[1] It is a member of the biarylpropylsulfonamide class of ampakines.[2]

LY-404,187 has been demonstrated to enhance cognitive function in animal studies, and has also shown effects suggesting antidepressant action as well as having possible application in the treatment of schizophrenia, Parkinson's disease and ADHD. These effects appear to be mediated through multiple mechanisms of action secondary to AMPA receptor potentiation, with a prominent effect seen in research being increased levels of BDNF in the brain.[3] It may therefore be continued on to human trials, although Eli Lilly has developed a whole family of biarylpropylsulfonamide derivatives and it is unclear at this stage which compound is most likely to be selected for further development.[4][5]

References

  1. ^ Jones N, O'Neill MJ, Tricklebank M, Libri V, Williams SC (August 2005). "Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging". Psychopharmacology (Berl.) 180 (4): 743–51. doi:10.1007/s00213-005-2254-y. PMID 15864556. 
  2. ^ Ryder JW, Falcone JF, Manro JR, Svensson KA, Merchant KM (October 2006). "Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors". J. Pharmacol. Exp. Ther. 319 (1): 293–8. doi:10.1124/jpet.106.105734. PMID 16803862. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16803862. 
  3. ^ Quirk JC, Nisenbaum ES. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Reviews. 2002 Fall;8(3):255-82. PMID 12353058
  4. ^ O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Current Drug Targets. CNS and Neurological Disorders. 2004 Jun;3(3):181-94. PMID 15180479
  5. ^ O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Current Drug Targets. 2007 May;8(5):603-20. PMID 17504104
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message